Swiss National Bank Raises Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Swiss National Bank grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 21.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 219,000 shares of the company’s stock after purchasing an additional 38,400 shares during the quarter. Swiss National Bank’s holdings in Vaxcyte were worth $17,927,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. CIBC Asset Management Inc lifted its stake in shares of Vaxcyte by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after purchasing an additional 110 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after buying an additional 260 shares during the last quarter. KBC Group NV increased its holdings in shares of Vaxcyte by 13.6% during the 3rd quarter. KBC Group NV now owns 2,683 shares of the company’s stock worth $307,000 after buying an additional 322 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the 4th quarter worth $28,000. Finally, Blue Trust Inc. increased its holdings in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after buying an additional 371 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares in the company, valued at $17,208,443.70. The trade was a 3.74 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,250 shares of company stock valued at $3,840,018. Insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group initiated coverage on Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Finally, Guggenheim restated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte has an average rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $74.72 on Wednesday. The business has a 50-day moving average of $81.77 and a 200-day moving average of $94.41. The company has a market capitalization of $9.62 billion, a PE ratio of -16.24 and a beta of 1.02. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, equities analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.